iTeos Therapeutics/ITOS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About iTeos Therapeutics

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its advanced program is inupadenant, also known as EOS-850, a next-generation adenosine 2A receptor (A2AR) antagonist tailored to overcome the specific adenosine-mediated immunosuppression found in the tumor microenvironment. Its program to initiate clinical trials is EOS-984, a potentially first-in-class small molecule focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1 (ENT1), a dominant transporter of adenosine on lymphocytes involved in T cell metabolism.

Ticker

ITOS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Michel Detheux

Employees

157

Headquarters

Watertown, United States

ITOS Metrics

BasicAdvanced
$605M
Market cap
-
P/E ratio
-$3.78
EPS
1.40
Beta
-
Dividend rate
$605M
1.39686
$18.75
$8.20
402K
13.51
-19.93%
-22.67%
-20.88%
1.109
1.117
-100.00%
-1,423.11%

What the Analysts think about ITOS

Analyst Ratings

Majority rating from 5 analysts.
Buy

ITOS Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$38M
25.25%
Profit margin
0.00%
NaN%

ITOS Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 14.82%
QuarterlyAnnual
Q4 22
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-
-$0.96
-$0.90
-$0.85
-$1.07
Expected
$0.33
-$1.03
-$1.20
-$1.03
-$1.26
Surprise
-
-6.80%
-25.21%
-17.73%
-14.82%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market openNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for iTeos Therapeutics stock?

iTeos Therapeutics (ITOS) has a market cap of $605M as of June 20, 2024.

What is the P/E ratio for iTeos Therapeutics stock?

The price to earnings (P/E) ratio for iTeos Therapeutics (ITOS) stock is 0 as of June 20, 2024.

Does iTeos Therapeutics stock pay dividends?

No, iTeos Therapeutics (ITOS) stock does not pay dividends to its shareholders as of June 20, 2024.

When is the next iTeos Therapeutics dividend payment date?

iTeos Therapeutics (ITOS) stock does not pay dividends to its shareholders.

What is the beta indicator for iTeos Therapeutics?

iTeos Therapeutics (ITOS) has a beta rating of 1.4. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the iTeos Therapeutics stock price target?

The target price for iTeos Therapeutics (ITOS) stock is $37.5, which is NaN% below the current price of $. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell iTeos Therapeutics stock

Buy or sell iTeos Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing